Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Heinlein, C. A. & Chang, C. Androgen receptor in prostate cancer. Endocr. Rev. 25, 276–308 (2004).
Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39 (2004).
Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787–790 (2009).
Kawamura, T. et al. Isolation and structure elucidation of a novel androgen antagonist, arabilin, produced by Streptomyces sp. MK756-CF1. J. Antibiot. 63, 601–605 (2010).
Lim, H. N. & Parker, K. A. Total synthesis of the potent androgen receptor antagonist (-)-arabilin: a strategic, biomimetic [1,7]-hydrogen shift. J. Am. Chem. Soc. 133, 20149–20151 (2011).
Ozers, M. S. et al. The androgen receptor T877A mutant recruits LXXLL and FXXLF peptides differently than wild-type androgen receptor in a time-resolved fluorescence resonance energy transfer assay. Biochemistry 46, 683–695 (2007).
Yoshida, T. et al. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Res. 65, 9611–9616 (2005).
Korpal, M. et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide). Cancer Discov. 3, 1030–1043 (2013).
Saito, S., Fujimaki, T., Panbangred, P., Igarashi, Y. & Imoto, M. Antarlides: a new type of androgen receptor (AR) antagonist that overcomes resistance to AR-targeted therapy. Angew. Chem. Int. Ed. 55, 2728–2732 (2016).
Lallous, N. et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients. Genome Biol. 17, 10 (2016).
Antonarakis, E. S. et al. Targeting the N-terminal domain of the androgen receptor: a new approach for the treatment of advanced prostate cancer. Oncologist 21, 1–9 (2016).
Balbas, M. D. et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2, e00499 (2013).
Moilanen, A. M. et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep. 5, 12007 (2015).
Tashiro, E. & Imoto, M. Chemical biology of compounds obtained from screening using disease models. Arch. Pharm. Res. 38, 1651–1660 (2015).
Acknowledgements
This work was partly supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (KAKENHI; JP23102006 to MI) and from the Japan Society for the Promotion of Science (KAKENHI; JP15H03116 to MI).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Fujimaki, T., Saito, S. & Imoto, M. Arabilin overcomes resistance to AR-targeted therapy. J Antibiot 70, 328–330 (2017). https://doi.org/10.1038/ja.2016.162
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/ja.2016.162
